182 related articles for article (PubMed ID: 30702752)
1. Development of a recombinant anti-Vel immunoglobulin M to identify Vel-negative donors.
van der Rijst MVE; Lissenberg-Thunnissen SN; Ligthart PC; Visser R; Jongerius JM; Voorn L; Veldhuisen B; Vidarsson G; van den Akker E; van der Schoot CE
Transfusion; 2019 Apr; 59(4):1359-1366. PubMed ID: 30702752
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a new human monoclonal antibody directed against the Vel antigen.
Danger Y; Danard S; Gringoire V; Peyrard T; Riou P; Semana G; Vérité F
Vox Sang; 2016 Feb; 110(2):172-8. PubMed ID: 26382919
[TBL] [Abstract][Full Text] [Related]
3. Recombinant polymeric IgG anti-Rh: a novel strategy for development of direct agglutinating reagents.
Montano RF; Penichet ML; Blackall DP; Morrison SL; Chintalacharuvu KR
J Immunol Methods; 2009 Jan; 340(1):1-10. PubMed ID: 18848836
[TBL] [Abstract][Full Text] [Related]
4. Anti-Vel reactivity diminished by adsorption with rabbit RBC stroma.
Mechanic SA; Maurer JL; Igoe MJ; Kavitsky DM; Nance ST
Transfusion; 2002 Sep; 42(9):1180-3. PubMed ID: 12430675
[TBL] [Abstract][Full Text] [Related]
5. Homozygosity for a null allele of SMIM1 defines the Vel-negative blood group phenotype.
Storry JR; Jöud M; Christophersen MK; Thuresson B; Åkerström B; Sojka BN; Nilsson B; Olsson ML
Nat Genet; 2013 May; 45(5):537-41. PubMed ID: 23563606
[TBL] [Abstract][Full Text] [Related]
6. SMIM1 underlies the Vel blood group and influences red blood cell traits.
Cvejic A; Haer-Wigman L; Stephens JC; Kostadima M; Smethurst PA; Frontini M; van den Akker E; Bertone P; Bielczyk-Maczyńska E; Farrow S; Fehrmann RS; Gray A; de Haas M; Haver VG; Jordan G; Karjalainen J; Kerstens HH; Kiddle G; Lloyd-Jones H; Needs M; Poole J; Soussan AA; Rendon A; Rieneck K; Sambrook JG; Schepers H; Silljé HHW; Sipos B; Swinkels D; Tamuri AU; Verweij N; Watkins NA; Westra HJ; Stemple D; Franke L; Soranzo N; Stunnenberg HG; Goldman N; van der Harst P; van der Schoot CE; Ouwehand WH; Albers CA
Nat Genet; 2013 May; 45(5):542-545. PubMed ID: 23563608
[TBL] [Abstract][Full Text] [Related]
7. Reactivity of FDA-approved anti-D reagents with partial D red blood cells.
Judd WJ; Moulds M; Schlanser G
Immunohematology; 2005; 21(4):146-8. PubMed ID: 16472014
[TBL] [Abstract][Full Text] [Related]
8. The Vel blood group system: a review.
Storry JR; Peyrard T
Immunohematology; 2017 Jun; 33(2):56-59. PubMed ID: 28657763
[TBL] [Abstract][Full Text] [Related]
9. Cold agglutinin activity is common among human monoclonal IgM Rh system antibodies using the V4-34 heavy chain variable gene segment.
Thorpe SJ; Boult CE; Stevenson FK; Scott ML; Sutherland J; Spellerberg MB; Natvig JB; Thompson KM
Transfusion; 1997; 37(11-12):1111-6. PubMed ID: 9426632
[TBL] [Abstract][Full Text] [Related]
10. Section 5: Structural/genetic analysis of mAbs to blood group antigens. Coordinator's report.
Siegel DL; Czerwinski M; Spitalnik SL
Transfus Clin Biol; 2002 Jan; 9(1):83-97. PubMed ID: 11889903
[TBL] [Abstract][Full Text] [Related]
11. The production of red blood cell alloantibodies in mice transfused with blood from transgenic Fyb-expressing mice.
Campbell-Lee SA; Liu J; Velliquette RW; Halverson GR; Shirey RS; Chaudhuri A; Reid ME; Ness PM; Baldwin WM
Transfusion; 2006 Oct; 46(10):1682-8. PubMed ID: 17002623
[TBL] [Abstract][Full Text] [Related]
12. SMIM1 missense mutations exert their effect on wild type Vel expression late in erythroid differentiation.
van der Rijst MVE; Abay A; Aglialoro F; van der Schoot CE; van den Akker E
Transfusion; 2021 Jan; 61(1):236-245. PubMed ID: 33128268
[TBL] [Abstract][Full Text] [Related]
13. SMIM1 polymorphisms in a donor population from southeast Brazil and their correlation with VEL expression.
Arnoni CP; De Paula Vendrame TA; Muniz JG; Gazito D; De Medeiros Person RD; Pereira Cortez AJ; Latini FRM; Castilho L
Blood Transfus; 2019 Jan; 17(1):60-65. PubMed ID: 29517970
[TBL] [Abstract][Full Text] [Related]
14. [Immunohematologic study and transfusion approach to patients with public antibodies].
Solves P; de la Rubia J; Arriaga F; Cervera J; Arnao M; Carpio N; Marty ML
Sangre (Barc); 1997 Feb; 42(1):25-9. PubMed ID: 9229799
[TBL] [Abstract][Full Text] [Related]
15. Section 4: Antibodies to other blood group antigens. Coordinator's report.
Daniels G
Transfus Clin Biol; 2002 Jan; 9(1):75-80. PubMed ID: 11889902
[No Abstract] [Full Text] [Related]
16. Impact of genetic variation in the SMIM1 gene on Vel expression levels.
Haer-Wigman L; Stegmann TC; Solati S; Ait Soussan A; Beckers E; van der Harst P; van Hulst-Sundermeijer M; Ligthart P; van Rhenen D; Schepers H; de Haas M; van der Schoot CE
Transfusion; 2015 Jun; 55(6 Pt 2):1457-66. PubMed ID: 25647324
[TBL] [Abstract][Full Text] [Related]
17. Performance of an automated solid-phase red cell adherence system compared with that of a manual gel microcolumn assay for the identification of antibodies eluted from red blood cells.
Finck RH; Davis RJ; Teng S; Goldfinger D; Ziman AF; Lu Q; Yuan S
Immunohematology; 2011; 27(1):1-5. PubMed ID: 22356479
[TBL] [Abstract][Full Text] [Related]
18. Molecular Screening for Vel- Blood Donors in Southwestern Germany.
Wieckhusen C; Rink G; Scharberg EA; Rothenberger S; Kömürcü N; Bugert P
Transfus Med Hemother; 2015 Nov; 42(6):356-60. PubMed ID: 26732700
[TBL] [Abstract][Full Text] [Related]
19. High-throughput strategy for molecular identification of Vel- blood donors employing nucleic acids extracted from plasma pools used for viral nucleic acid test screening.
Dezan MR; Dinardo CL; Bosi SR; Vega S; Salles NA; Mendrone-Júnior A; Levi JE
Transfusion; 2016 Jun; 56(6):1430-4. PubMed ID: 27060345
[TBL] [Abstract][Full Text] [Related]
20. Patients with anti-Vel--immunohematological characterization and transfusion management.
Lynen R; Simson G; Quentin SH; Schulte B; The LG; Neumeyer H
Beitr Infusionsther; 1990; 26():377-9. PubMed ID: 1703877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
